Madison, Wisconsin, United States Bruker appeared to be the Corporate Investor, which was created in 1960. The fund was located in North America if to be more exact in United States. The main office of represented Corporate Investor is situated in the Madison.
For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline GeneFormatics We can highlight the next thriving fund investment areas, such as Biotechnology.
Related Funds
| Fund Name | Location |
| Industry Capital | California, San Francisco, United States |
| Jiancheng Xinxi | Beijing, China, Haidian |
| MAIF Investissement Social et Solidaire | France, Ile-de-France, Paris |
| Oxantium Ventures | District of Columbia, United States, Washington |
| Trilantic North America | New York, New York, United States |
| UPS Strategic Enterprise Fund | Atlanta, Georgia, United States |
| Vsquared Ventures | Bayern, Germany, Munich |
| XLR Capital | - |
| Yi Ling Capital | China, Chongqing, Chongqing Shi |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Tome Biosciences | $213M | 12 Dec 2023 | Watertown, Massachusetts, United States | ||
Mercy BioAnalytics | $41M | 03 Apr 2023 | Natick, Massachusetts, United States | ||
KIYATEC | $18M | 12 Dec 2022 | Greenville, South Carolina, United States | ||
Haystack Oncology | $56M | 16 Nov 2022 | Baltimore, Maryland, United States | ||
Navignostics AG | $8M | 09 Nov 2022 | Zürich, Zurich, Switzerland | ||
Adeptrix | 06 Jan 2021 | Beverly, Massachusetts, United States | |||
Ionpath | $18M | 24 Sep 2020 | California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Tome Biosciences | $213M | 12 Dec 2023 | Watertown, Massachusetts, United States | ||
Mercy BioAnalytics | $41M | 03 Apr 2023 | Natick, Massachusetts, United States | ||
KIYATEC | $18M | 12 Dec 2022 | Greenville, South Carolina, United States | ||
Haystack Oncology | $56M | 16 Nov 2022 | Baltimore, Maryland, United States | ||
Navignostics AG | $8M | 09 Nov 2022 | Zürich, Zurich, Switzerland | ||
Adeptrix | 06 Jan 2021 | Beverly, Massachusetts, United States | |||
Ionpath | $18M | 24 Sep 2020 | California, United States |
